Sponsored by
We're glad to announce the FDA recently approved the Expanded Access Program (EAP) for gallium maltolate, an investigational therapy for glioblastoma. The EAP details can be found here and our webinar on the therapy is available here. If you are interested in participating, please email eap@imagingbiometrics.com.
The Musella Foundation gave a grant to help get the EAP started, but our grant covers only part of the program costs. Patients will still be charged a portion of the costs. If any organizations or individuals want to help us with further funding in order to make the EAP free for patients, please contact me! Donations directly to the fund can be made here.